Data Insights

TSC-200 HLA-A*02:01 by TScan Therapeutics for Metastatic Melanoma: Likelihood of Approval

TSC-200 HLA-A*02:01 is under clinical development by TScan Therapeutics and currently in Phase I for Metastatic Melanoma. According to GlobalData,...

Data Insights

TSC-200 HLA-A*02:01 by TScan Therapeutics for Head And Neck Cancer: Likelihood of Approval

TSC-200 HLA-A*02:01 is under clinical development by TScan Therapeutics and currently in Phase I for Head And Neck Cancer. According...

Data Insights

TSC-200 HLA-A*02:01 by TScan Therapeutics for Cervical Cancer: Likelihood of Approval

TSC-200 HLA-A*02:01 is under clinical development by TScan Therapeutics and currently in Phase I for Cervical Cancer. According to GlobalData,...

Data Insights

TSC-101 by TScan Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

TSC-101 is under clinical development by TScan Therapeutics and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - TSC-101 in Myelodysplastic Syndrome

Data Insights

TSC-101 by TScan Therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

TSC-101 is under clinical development by TScan Therapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...

Likelihood of Approval and Phase Transition Success Rate Model - TSC-101 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

TSC-101 by TScan Therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

TSC-101 is under clinical development by TScan Therapeutics and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...

Likelihood of Approval and Phase Transition Success Rate Model - TSC-101 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Data Insights

TSC-204 HLA-A*02:01 by TScan Therapeutics for Cervical Cancer: Likelihood of Approval

TSC-204 HLA-A*02:01 is under clinical development by TScan Therapeutics and currently in Phase I for Cervical Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - TSC-204 HLA-A*02:01 in Cervical Cancer

Data Insights

TSC-204 HLA-A*02:01 by TScan Therapeutics for Metastatic Ovarian Cancer: Likelihood of Approval

TSC-204 HLA-A*02:01 is under clinical development by TScan Therapeutics and currently in Phase I for Metastatic Ovarian Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - TSC-204 HLA-A*02:01 in Metastatic Ovarian Cancer

Data Insights

TSC-204 HLA-A*02:01 by TScan Therapeutics for Anal Cancer: Likelihood of Approval

TSC-204 HLA-A*02:01 is under clinical development by TScan Therapeutics and currently in Phase I for Anal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - TSC-204 HLA-A*02:01 in Anal Cancer

Data Insights

TSC-204 HLA-A*02:01 by TScan Therapeutics for Metastatic Melanoma: Likelihood of Approval

TSC-204 HLA-A*02:01 is under clinical development by TScan Therapeutics and currently in Phase I for Metastatic Melanoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - TSC-204 HLA-A*02:01 in Metastatic Melanoma

Data Insights

TSC-204 HLA-A*02:01 by TScan Therapeutics for Head And Neck Cancer: Likelihood of Approval

TSC-204 HLA-A*02:01 is under clinical development by TScan Therapeutics and currently in Phase I for Head And Neck Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - TSC-204 HLA-A*02:01 in Head And Neck Cancer

Data Insights

TSC-100 by TScan Therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

TSC-100 is under clinical development by TScan Therapeutics and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...

Likelihood of Approval and Phase Transition Success Rate Model - TSC-100 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Data Insights

TSC-203 HLA-A*02:01 by TScan Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

TSC-203 HLA-A*02:01 is under clinical development by TScan Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - TSC-203 HLA-A*02:01 in Non-Small Cell Lung Cancer

Data Insights

TSC-100 by TScan Therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

TSC-100 is under clinical development by TScan Therapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...

Likelihood of Approval and Phase Transition Success Rate Model - TSC-100 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

TSC-203 HLA-A*02:01 by TScan Therapeutics for Head And Neck Cancer: Likelihood of Approval

TSC-203 HLA-A*02:01 is under clinical development by TScan Therapeutics and currently in Phase I for Head And Neck Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - TSC-203 HLA-A*02:01 in Head And Neck Cancer

Data Insights

TSC-203 HLA-A*02:01 by TScan Therapeutics for Melanoma: Likelihood of Approval

TSC-203 HLA-A*02:01 is under clinical development by TScan Therapeutics and currently in Phase I for Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - TSC-203 HLA-A*02:01 in Melanoma

Data Insights

TSC-203 HLA-A*02:01 by TScan Therapeutics for Cervical Cancer: Likelihood of Approval

TSC-203 HLA-A*02:01 is under clinical development by TScan Therapeutics and currently in Phase I for Cervical Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - TSC-203 HLA-A*02:01 in Cervical Cancer

Data Insights

TSC-203 HLA-A*02:01 by TScan Therapeutics for Ovarian Cancer: Likelihood of Approval

TSC-203 HLA-A*02:01 is under clinical development by TScan Therapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - TSC-203 HLA-A*02:01 in Ovarian Cancer

Data Insights

TSC-100 by TScan Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

TSC-100 is under clinical development by TScan Therapeutics and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - TSC-100 in Myelodysplastic Syndrome

Data Insights

TSC-203 HLA-A*02:01 by TScan Therapeutics for Anal Cancer: Likelihood of Approval

TSC-203 HLA-A*02:01 is under clinical development by TScan Therapeutics and currently in Phase I for Anal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - TSC-203 HLA-A*02:01 in Anal Cancer